Company Control Change - *ST Ningke has experienced a significant stock price increase, achieving five consecutive trading limits. The company is currently in the execution phase of its restructuring plan [1][3] - The company announced that its controlling shareholder and actual controller will change, with Liu Xirong becoming the new actual controller [1][3] - On December 16, the company disclosed that 882 million shares, accounting for 54.64% of the total share capital, were transferred from the management's securities account to the designated securities account of the restructuring investor [1][3] Financial Misrepresentation - In 2022, the company inflated its operating revenue by 76.5941 million yuan and its total profit by 77.222 million yuan, representing 11.25% and 46.59% of the respective figures for that period [1][3] - The company failed to disclose significant events in a timely manner, particularly regarding major debts and the suspension of key business operations of its subsidiaries [1][3] Investor Compensation - The successful restructuring of *ST Ningke is expected to benefit investor compensation efforts. The restructuring plan is set to be executed until December 31, 2025 [2][4] - Investors who meet specific criteria can actively participate in compensation registration to recover losses incurred due to the company's financial misrepresentation [2][4] - Legal representation by experienced lawyers, such as Liu Peng, is emphasized as crucial for maximizing investor rights and compensation outcomes [2][4]
宁科生物进入重整执行阶段,曾被监管处罚维权征集中